Cargando…
Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
BACKGROUND: The therapeutic use of [(131)I]meta-iodobenzylguanidine ([(131)I]MIBG) is often accompanied by hematological toxicity, mainly consisting of persistent and severe thrombocytopenia. While MIBG accumulates in neuroblastoma cells via selective uptake by the norepinephrine transporter (NET),...
Autores principales: | Blom, Thomas, Meinsma, Rutger, Rutgers, Marja, Buitenhuis, Corine, Dekken-Van den Burg, Marieke, van Kuilenburg, André B. P., Tytgat, Godelieve A. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343696/ https://www.ncbi.nlm.nih.gov/pubmed/32642907 http://dx.doi.org/10.1186/s13550-020-00662-w |
Ejemplares similares
-
Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021) -
Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
por: Kuin, A, et al.
Publicado: (1999) -
Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis
por: Wozniak, Greta, et al.
Publicado: (2011) -
Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs)
por: Jannini, Tommaso B., et al.
Publicado: (2022) -
A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG)
por: Sheikholislam, Zahra, et al.
Publicado: (2013)